Medical Oncology

Uzm. Dr. Gözde Ağdaş

Doctor and researcher SBÜ. Van Eğitim ve Araştırma Hastanesi Van
Carcinoma, Non-Small-Cell LungLung NeoplasmsStomach Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Carcinoma, Non-Small-Cell Lung 4 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Lung Neoplasms 4 publications
  • Stomach Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionSBÜ. Van Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
  • Area of workCarcinoma, Non-Small-Cell LungExtracted from 4 publications · Model version —From source
  • Publications27 publicationsOpenAlex, ORCID, Europe PMCFrom source
  • ORCID0000-0001-9771-6483ORCIDFrom source
  • Last synchronised5 November 2026 10:47https://vaneah.saglik.gov.tr/TR-47354/tibbi-onkoloji.html#gozde-agdassaglik.gov.tr

Scientific work

Publications on Carcinoma, Non-Small-Cell Lung

27 publications

  1. Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16868-5 Open-access full textSource: OpenAlex

  2. Meme Kanseri

    Akademisyen Kitabevi eBooks, 2026

    DOI 10.37609/akya.3852 Open-access full textSource: OpenAlex

  3. Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020642 PMID 41598581 Open-access full textSource: ORCID

  4. Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients

    Scientific reports, 2026

    DOI 10.1038/s41598-026-50526-x PMID 42103792 Open-access full textSource: Europe PMC

  5. The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer

    Discover oncology, 2026

    DOI 10.1007/s12672-026-04705-x PMID 41721952 Open-access full textSource: Europe PMC

  6. Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab

    Scientific reports, 2026

    DOI 10.1038/s41598-026-48955-9 PMID 41981174 Open-access full textSource: Europe PMC

  7. Impact of renin-angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non-small cell lung cancer

    Expert review of anticancer therapy, 2026

    DOI 10.1080/14737140.2026.2615853 PMID 41511755 2 citations (Europe PMC) Source: ORCID

  8. Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumab

    Discover Oncology, 2026

    DOI 10.1007/s12672-026-04859-8 PMID 42014558 Open-access full textSource: OpenAlex

  9. Integrating molecular and clinical determinants of survival in a real-world glioblastoma cohort

    Journal of Medicine and Palliative Care, 2026

    DOI 10.47582/jompac.1850445 Open-access full textSource: ORCID

  10. IMMUNE-RELATED ADVERSE EVENTS AND THEIR MANAGEMENT IN CANCER PATIENTS AGED 75 YEARS AND OLDER RECEIVING IMMUNOTHERAPY

    Acta Medica Nicomedia, 2026

    DOI 10.53446/actamednicomedia.1906747 Open-access full textSource: ORCID

View all 27 publications